Sign up
Pharma Capital

Onzima Ventures PLC says N4 Pharma extends relationship with Uniquest

N4's aim now is to develop strong commercial propositions using its intellectual property and seek partnerships and funds to take forward specific projects.
mRNA is an exciting area of therapeutic treatment in oncology

N4 Pharma, one of the portfolio companies of investment firm Onzima Ventures PLC (LON:ONZ), has extended its relationship with the University of Queensland (Uniquest).

N4 now has the exclusive global rights to commercialise the university's nano particle vaccine delivery system for messenger ribonucleic acid (mRNA) particles; the UK firm already had the rights for the Aussie uni's plasmid DNA (pDNA) and certain subunit vaccines.

Messenger RNA particles are molecules that carry DNA code to other parts of the RNA cell for processing. A pDNA, meanwhile, is a double-stranded DNA molecule that is discrete from a cell's chromosomal DNA.

Under the latest agreement N4 Pharma will undertake further research and experimentation with Uniquest to develop a strong in-vitro (test tube) data package demonstrating the ability of these vectors to achieve high protective loading of pDNA and mRNA and demonstrate their strong transfection capability.

“mRNA is an exciting area of therapeutic treatment in oncology and early encouraging results with our plasmid DNA research show strong pDNA loading onto the silica vesicle and excellent transfection being achieved,” said Nigel Theobald, chief executive of N4 Pharma.

“Over the next few months we will continue to undertake experiments to demonstrate the capability of our vectors for both pDNA and mRNA, publishing the data when we can with a view to looking to engage with potential partners in the second half of 2016 to either work with their own particles or potentially acquire the rights to particles ourselves which we can then seek to take forward using these vectors,” Theobald added.

Onzima owns 49% of N4 Pharma.


Register here to be notified of future N4P Company articles
View full N4P profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.